Brii expands in infectious via deals with Vir, VBI, WuXi Biologics

Brii Biosciences (Shanghai, China) is broadening its pipeline in HBV and other infectious diseases through a series of new and expanded deals announced Dec. 6, even as CEO Zhi Hong said the company is looking to expand into another therapeutic area.

Brii launched in May with $260 million and three initial partnerships to bring infectious diseases to the forefront of innovation in China: one with the AliHealth healthcare arm of the Alibaba Group Holding Ltd. (NYSE:BABA), another with infectious disease start-up Vir Biotechnology Inc. (San Francisco, Calif.), and a memorandum of understanding with Chinese CROs Wuxi AppTec Co. Ltd. (Shanghai:603259) and WuXi Biologics Inc. (HKSE:2269) (see "Partnering on a Mission")...